The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1443
In Brief: Heptavalent Botulism Antitoxin
Download PDF:   US English
 Select a term to see related articles  BabyBIG   botulism antitoxin 

The FDA has approved the use of an equine heptavalent botulism antitoxin (BAT, Cangene Corporation). The new antitoxin includes antibodies against all 7 botulinum neurotoxin types (A-G). A human-derived antitoxin (BabyBIG) has been available for years for infant botulism. The heptavalent product is now the preferred antitoxin for adult botulism. It is a solution of immunoglobulin fragments obtained from equine plasma that has gone through several steps of purification and viral inactivation. (The use of immunoglobulin fragments reduces side effects compared to intact immunoglobulin.) BAT is available from the CDC through state and local health departments.

© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.